

**GLOBAL HEALTH LIMITED**

ABN 75 091 377 892

**NOTICE OF ANNUAL GENERAL MEETING**

Notice is hereby given that a general meeting of the members of Global Health Limited (**Company**) will be held as shown below:

Date: **21 November 2019 (Thursday)**

Time: **1:00pm (AEDT)**

Place: **Institute of Chartered Accountants Australia  
Level 18, 600 Bourke St, Melbourne, Victoria 3000**

---

**ITEMS OF BUSINESS**

**1) Receive the Reports for the Year Ended 30 June 2019**

To receive and consider the Annual Financial Report, the Directors' Report and the Independent Audit Report of the Company and its controlled entities for the financial year ended 30 June 2019.

**2) Remuneration Report 2019**

To consider and, if thought fit, to pass the following resolution as a non-binding resolution:

*'That the Remuneration Report for the financial year ended 30 June 2019 (as set out in the Directors' Report) be adopted'.*

Voting exclusion

The Company will disregard any votes cast on this resolution by all directors and key management personnel, being persons who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, and any of their respective nominees or associates. The Company will also disregard the votes cast on this resolution by all closely related parties of directors and key management personnel. However the Company need not disregard a vote if it is cast by:

- (a) that person (excluded from voting) as proxy, appointed in writing for a person who is entitled to vote, in accordance with the express directions on the proxy form and is not cast on behalf of a person excluded from voting or their closely related parties; or
- (b) the person chairing the meeting who is appointed as proxy and the proxy:
  - (i) does not specify the way the proxy is to vote on the resolution; and
  - (ii) expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of the key management personnel for the Company.

Please note that the Chairman of the Meeting intends to vote undirected proxies in favour of all resolutions.

If the Chairman of the Meeting is appointed as your proxy you are expressly authorising the Chairman of the Meeting to exercise your proxy even if the resolution is connected directly or indirectly with the remuneration of a member of key management personnel.

**3) Re-election of Director**

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

**GLOBAL HEALTH LIMITED**  
ABN 75 091 377 892

## NOTICE OF ANNUAL GENERAL MEETING 2019

*'That in accordance with the provisions of the Company's Constitution, Mr. Steven Pynt retires by rotation and being eligible is hereby re-elected as a Director of the Company'.*

### 4) Extension of Employee Share Option Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*'That, for the purposes of ASX Listing Rule 7.2 Exception 9 and for all other purposes, the Company authorises the directors to issue options to acquire fully paid shares in the Company for another three years commencing on 21 November 2019 upon and subject to the terms of the Employee Share Option Plan, which are summarised in the Explanatory Statement accompanying this Notice'.*

1,000,000 options have been issued under the Employee Share Option Plan since the date of the last shareholder approval on 29 November 2016, all of which remain valid.

#### Voting exclusion

For the purposes of ASX Listing Rule 7.2 Exception 9 and Section 224 of the Corporations Act, the Company will disregard any votes cast in favour of this resolution by or on behalf of any director of the Company (except one who is ineligible to participate in any employee incentive scheme in relation to the Company), or an associate of any such director. However the Company need not disregard a vote if it is cast by:

- (a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- (b) the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

### 5) Extension of Exempt Employee Share Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

*'That, for the purposes of ASX Listing Rule 7.2 Exception 9 and for all other purposes, the Company authorises the directors to issue shares in the Company for another three years commencing on 21 November 2019 upon and subject to the terms of the Exempt Employee Share Plan, which are summarised in the Explanatory Statement accompanying this Notice'.*

No shares have been issued under the Exempt Employee Share Plan since the date of the last shareholder approval on 29 November 2016.

#### Voting exclusion

For the purposes of ASX Listing Rule 7.2 Exception 9 and Section 224 of the Corporations Act, the Company will disregard any votes cast in favour of this resolution by or on behalf of any director of the Company (except one who is ineligible to participate in any employee incentive scheme in relation to the Company), or an associate of any such director. However the Company need not disregard a vote if it is cast by:

- (a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- (b) the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

**GLOBAL HEALTH LIMITED**  
ABN 75 091 377 892

## NOTICE OF ANNUAL GENERAL MEETING 2019

### 6) Special Resolution for Approval of Additional 10% Placement Capacity under Listing Rule 7.1A

To consider and, if thought fit, to pass the following resolution as a special resolution:

*'That for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval be given for the issue of equity securities of up to 10% of the Company's share capital calculated in accordance with Listing Rule 7.1A, and on the terms and conditions set out in the Explanatory Statement'.*

The Company previously obtained shareholder approval under Listing Rule 7.1A at the last Annual General Meeting on 22 November 2018.

#### Voting exclusion

The Company will disregard any votes cast in favour of this resolution by or on behalf of any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary shares in the Company), and any associate of any such person.

However, the Company need not disregard a vote if the vote is cast by:

- (a) a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- (b) the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

At the date of finalisation of the notice, the Company has not approached any particular existing shareholder or an identifiable class of existing shareholders to participate in any issue of shares. No existing shareholder's vote will therefore be excluded under the voting exclusion.

The Board recommends that you vote in favour of each of the proposed resolutions and the Directors intend to vote any undirected proxies in favour of each proposed resolution.

The Explanatory Statement and Notes which accompany and form part of this Notice of Meeting more fully describe the matters to be considered at the Annual General Meeting.

This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to contact the Company Secretary on +613 9675 0600.

By Order of the Board



Sam Butcher  
Company Secretary  
10 October 2019

## NOTES

### Proxies

A member who is entitled to attend and vote at the Annual General Meeting may appoint a proxy.

A proxy need not be a member of the Company.

A proxy can be either an individual or a body corporate. If you appoint a body corporate as your proxy, that body corporate will need to ensure that it:

- appoints an individual as its corporate representative to exercise its powers at meetings, in accordance with section 250D of the Corporations Act 2001 (Cth); and
- provides satisfactory evidence of the appointment of its corporate representative prior to commencement of the meeting.

If satisfactory evidence of appointment as corporate representative is not received before the meeting, then the body corporate (through its representative) will not be permitted to act as your proxy. If a shareholder is entitled to cast two or more votes they may appoint two proxies and may specify the percentage or number of votes each proxy is appointed to exercise. If the proxy appointments do not specify the proportion or number of the member's voting rights that each proxy may exercise, each proxy may exercise half of the member's votes.

A form of appointment of proxy is enclosed. To be effective, the proxy form (and, if the appointment is signed by the appointer's attorney, the authority under which it was signed or a certified copy of the authority) must be received by the Company's share registry, Link Market Services Limited, by **1:00pm (AEDT) on Tuesday, 19 November 2019**.

Where more than one proxy is to be appointed or where voting intentions cannot be adequately expressed using the enclosed proxy form, an additional form of proxy is available on request from the Share Registry.

The completed Proxy Form may be:

Mailed/delivered to the Company's share registry, Link Market Services Limited at:

Street Address:

Level 12  
680 George Street  
Sydney NSW 2000

Postal Address:

Locked Bag A14  
Sydney South  
NSW 1235

Faxed to Link Market Services Limited on fax: +612 9287 0309.

Lodged On-Line: Lodge your vote on-line at Global Health Limited's Share Registry website [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au). If you lodge your proxy electronically you will not need to return your proxy form by mail or fax.

### Corporate Representatives

A corporation may elect to appoint an individual to act as its representative in accordance with section 250D of the Corporations Act in which case the Company will require a Certificate of Appointment of Corporate Representative executed in accordance with the Corporations Act. The Certificate must be lodged with the Company before the meeting or at the registration desk on the day of the meeting. The Company will retain the certificate.

### Entitlement to Vote

*In accordance with Regulation 7.11.37 of the Corporations Regulations the Directors have set a date to determine the identity of those entitled to attend and vote at the meeting. That date is 7:00pm (AEDT) on 19 November 2019.*

## EXPLANATORY STATEMENT

This Explanatory Statement has been prepared for the information of Shareholders in relation to the business to be conducted at the Company's Annual General Meeting. The purpose of this Explanatory Statement is to provide Shareholders with information that is reasonably required by Shareholders to decide how to vote upon the resolutions.

The Directors recommend that Shareholders read this Explanatory Statement before determining whether or not to support the resolutions.

### 1) Reports for the Year Ended 30 June 2019

This item is self-explanatory. It is intended to provide an opportunity for Shareholders to raise questions on the reports themselves and on the performance of the Company generally.

### 2) Remuneration Report 2019

As required by sections 249L(2) and 250R(2) of the Corporations Act, a resolution that the Company's Remuneration Report be adopted must be put to the vote. The Remuneration Report is set out in the Directors' Report contained in the Company's 2019 Annual Report.

Section 250R(3) of the Corporations Act provides that the vote on the resolution is advisory and not binding on the Company or the Directors.

Section 250R(4) of the Corporations Act provides that votes on the resolution must not be cast (in any capacity) by or on behalf of members of key management personnel or their closely related parties. However, a vote may be cast by such a person as a proxy for a person who is entitled to vote on this Resolution, appointed by way of a shareholder voting form that directs how the proxy is to vote on this Resolution. Any undirected proxies held by Directors or by other Key Management Personnel or their closely-related parties for the purposes of this Resolution will not be voted. This prohibition does not apply to the Chairman of the meeting who may vote directed and undirected proxies in favour of the resolution, providing that the shareholder expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel for the relevant entity.

'Key Management Personnel' and 'closely related party' for the purposes of the Corporations Act are widely defined. They include directors and key management personnel of a public company and family members of directors and key management personnel. Closely-related parties include entities over which a director or key management personnel maintains control.

Under the Corporations Act, where a company's remuneration report receives a 'No' vote of 25% or more at two consecutive annual general meetings, a resolution must then be put to the shareholders at that second annual general meeting as to whether another meeting ('spill meeting') should be held within 90 days at which all directors (other than the managing director) who were in office at the date of approval of the relevant directors' report must stand for re-election.

A reasonable opportunity will be provided for discussion of the Remuneration Report at the Annual General Meeting.

The Company encourages all shareholders to cast their votes in relation to this Resolution and if shareholders choose to appoint a proxy, shareholders are encouraged to direct their proxy how to vote on the Resolution by marking either "For", "Against" or "Abstain" on the proxy form.

The Chairman of the meeting intends to vote undirected proxies in favour of this Resolution.

**NOTICE OF ANNUAL GENERAL MEETING 2019**

*Explanatory Statement*

**3) Re-election of Director**

This Resolution seeks Shareholder approval for the re-election of Mr Steven Pynt as a Director of the Company.

Clause 11.3 of the Company's Constitution provides that one third of the Directors shall retire from office at every Annual General Meeting of the Company and clause 11.4 provides that such Director is eligible for re-election at that meeting. If approved by Shareholders, the appointments will take effect immediately following the end of the Annual General Meeting.

Mr Pynt is the Chairman of the board and a member of the Audit Committee. He is a director of the Perth legal firm, MP Commercial Lawyers, and his main area of practice is in commercial law including corporations' law, franchising and contracts. He was formerly a member of the Racing Penalties Appeals Tribunal and Chairman of the Commercial Tribunal of WA. He is also a director Ephraim Resources Limited (under Administration) and Gondwana Resources Limited.

Mr Pynt has been a Director of the Company since 2000.

The Chairman of the meeting intends to vote undirected proxies in favour of this resolution.

**4) Extension of Employee Share Option Plan**

As an incentive to employees and consultants of the Company, an Employee Share Option Plan was adopted by the Company on its listing in April 2000. The Employee Share Option Plan was previously extended and will expire on 29 November 2019.

ASX Listing Rule 7.1 requires that a company obtain shareholder approval prior to the issue of securities representing more than 15% of the issued capital of the Company. ASX Listing Rule 7.2 sets out a number of exceptions to Listing Rule 7.1, one of which (Exception 9) is an issue of shares or options under an employee incentive scheme if, within 3 years before the date of issue, the shareholders of the Company approved the issue of securities under the scheme.

The key points of the Employee Share Option Plan can be summarised as follows:

- the Directors may issue Options to a Director, Officer or Employee of the Company or a Controlled Entity if the total number of shares the subject of Options, when aggregated with:
  - (a) the number of shares in the same class which would be issued were each outstanding offer or invitation or option to acquire unissued shares in the Company, being an offer or invitation made or Option acquired pursuant to the Plan or any other employee or executive share plan extended only to Eligible Persons, to be accepted or exercised (as the case may be); and
  - (b) the number of shares in the same class issued during the previous five (5) years pursuant to the Plan or any other employee or executive share plan extended only to Eligible Persons,  
would not exceed five per cent (5%) of the total number of issued shares in the Company as at the time of the proposed offer or issue;
- the Plan can be extended for durations of not greater than 3 years;
- options issued under the Plan are for a minimum of 2 years and a maximum of 5 years.

1,000,000 options have been issued under the Employee Share Option Plan since the date of the last shareholder approval on 29 November 2016, all of which remain valid.

Your Directors seek approval to extend the Employee Share Option Plan for a further 3 years from the date of the 2019 AGM, in accordance with the provisions of the plan thereby giving

the Company greater flexibility to make future issues of securities. A copy of the plan is available from the Company's website at: [www.global-health.com](http://www.global-health.com).

**5) Extension of Exempt Employee Share Plan**

As an incentive to employees and consultants of the Company, an Exempt Employee Share Plan was adopted by the Company on listing of the Company in April 2000. The Exempt Employee Share Plan was previously extended and will expire on 29 November 2019.

ASX Listing Rule 7.1 requires that a company obtain shareholder approval prior to the issue of securities representing more than 15% of the issued capital of the Company. ASX Listing Rule 7.2 set out a number of exceptions to Listing Rule 7.1, one of which (Exception 9) is an issue of shares or options under an employee incentive scheme if, within 3 years before the date of issue, the shareholders of the Company approved the issue of securities under the scheme.

The key points of the Exempt Employee Share Plan can be summarised as follows:

- the Directors may issue shares to a Director, Officer or Employee of the Company or a Controlled Entity in accordance with the Plan if the total number of Shares which is the subject of the offer or issue, when aggregated with:
  - (a) the number of shares in the same class which would be issued were each outstanding offer or invitation or option to acquire unissued shares in the Company, being an offer or invitation made or Option acquired pursuant to the Plan or any other employee or executive share plan extended only to Eligible Persons, to be accepted or exercised (as the case may be); and
  - (b) the number of shares in the same class issued during the previous five (5) years pursuant to the Plan or any other employee or executive share plan extended only to Eligible Persons,would not exceed five per cent (5%) of the total number of issued Shares in the Company as at the time of the proposed offer or issue;
- the Plan can be extended for durations of not greater than 3 years;
- the maximum value of shares that may be issued to any Eligible Person in any financial year is \$1,000.

The Company has not issued any shares under the Plan, since the date of last approval on 29 November 2016.

Your Directors seek approval to extend the Exempt Employee Share Plan for a further 3 years from the date of the AGM of 2019, in accordance with the provisions of the plan thereby giving the Company greater flexibility to make future issues of securities. A copy of the plan is available from the Company's website at: [www.global-health.com](http://www.global-health.com)

**6) Approval of Capacity to Issue Additional 10% of Issued Shares under Listing Rule 7.1A**

The Company is seeking shareholder approval pursuant to this Resolution to issue up to an additional 10% of the issued share capital of the Company under ASX Listing Rule 7.1A (**Additional 10%**). This is a special resolution and requires approval of 75% of the votes cast by shareholders present and eligible to vote.

The only securities that the Additional 10% can cover are existing quoted securities, namely ordinary fully paid shares.

The effect of this Resolution, if carried will be to allow the Directors to issue equity securities under Listing Rule 7.1A during the period of 12 months following the Annual General Meeting without using its 15% placement capacity under Listing Rule 7.1. An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company is an eligible entity.

**Share Issue Capacity**

As at the date of this Notice of Meeting, the Company has 33,678,592 shares on issue and therefore, in addition to any other shares which it can issue under the permitted exceptions to Listing Rules 7.1 and 7.1A, it has the capacity to issue:

- 5,051,788 shares under Listing Rule 7.1; and
- subject to shareholder approval being obtained under this resolution, 3,367,859 shares under Listing Rule 7.1A.

The actual number of Shares that the Company will have the capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the shares in accordance with the following formula (as prescribed by Listing Rule 7.1A.2):

$$(A \times D) - E$$

where:

**A** is the number of fully paid ordinary securities on issue 12 months before the date of issue or agreement:

- plus the number of fully paid shares issued in the 12 months under an exception in Listing Rule 7.2;
- plus the number of partly paid shares that became fully paid in the 12 months;
- plus the number of fully paid shares issued in the 12 months with the approval of holders of shares under Listing Rule 7.1 or 7.4. This does not include an issue of fully paid shares under the Company's 15% placement capacity without shareholder approval;
- less the number of fully paid shares cancelled in the 12 months,  
(note that A has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity);

**D** is 10%; and

**E** is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that are *not* issued with the approval of holders of ordinary securities under Listing Rule 7.1 or 7.4.

Since 21 November 2018, the Company has issued 208,333 ordinary shares, which represented 0.62% of the total number of shares on issue as at 21 November 2018. On 23 January 2019 the Company issued 208,333 fully paid ordinary shares to Abaki Pty Ltd as partial consideration for the acquisition of medical software and associated assets under a Business and Asset Sale Agreement dated 23 July 2015. At the current share price of \$0.155, the current value of the 208,333 shares issued to Abaki Pty Ltd is \$32,292.

On 4 October 2019, the Company announced a pro rata entitlement offer to issue up to 8,419,648 new shares and up to 4,209,824 new options to Eligible Shareholders. The offer is scheduled to close before the AGM on 4 November 2019.

**Minimum Issue Price**

In accordance with Listing Rule 7.1A, shares issued by the Company under an Additional 10% placement can only be issued at a price that is not less than 75% of the VWAP (volume weighted average price) of the shares calculated over the 15 trading days on which trades in its shares were recorded immediately before:

- the date on which the issue price of the shares is agreed; or
- the issue date (if the shares are not issued within five trading days of the date on which the issue price is agreed).

**NOTICE OF ANNUAL GENERAL MEETING 2019**

*Explanatory Statement*

Period of Validity

Shareholder approval under Listing Rule 7.1A is valid from the date of this AGM until the earlier to occur of:

- 12 months after the date of the AGM; or
- the date of approval by shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking), or such longer period if allowed by ASX.

Provided that on the date of the AGM the Company meets the criteria of market capitalisation of \$300 million or less and is not included in the S&P/ASX 300 Index, shareholder approval under Listing Rule 7.1A does not lapse if the Company's market capitalisation subsequently exceeds \$300 million or it is included in the S&P/ASX 300 Index at some time during the above periods.

Dilution to existing shareholdings

If this Resolution is approved by shareholders and the Company issues shares under the Additional 10%, there is a risk of shareholder's interests being diluted. Further, as the market price of the Company's Shares may be significantly lower on the issue date than on the date of AGM approval, and because the shares may be issued at a price that is at a discount to the market price on the issue date, there is a risk that the Additional 10% placement may raise less funding than it would based on current market prices.

As required by Listing Rule 7.3A.2, the table below shows a number of hypothetical scenarios under an Additional 10% placement where variable 'A' in the formula in Listing Rule 7.1A.2 (representing the Company's share capital) increases by either 50% or 100%, and the share price decreases by 50% or increases by 100% from the approximate share price as at the date of finalisation of this Notice of Meeting.

Dilution Table - Hypothetical Potential Dilution Scenarios

Share Capital (Variable 'A' in Listing Rule 7.1A.2)	Funds expected to be raised at:		
	50% decrease in share price \$0.078	Current share price \$0.155	100% increase in share price \$0.31
Current: A = <b>33,678,592</b> Additional 10% = <b>3,367,859</b>	\$262,693	\$522,018	\$1,044,036
If A increases by 50% = <b>50,517,888</b> Additional 10% = <b>5,051,789</b>	\$394,039	\$783,027	\$1,566,055
If A increases by 100% = <b>67,357,184</b> Additional 10% = <b>6,735,718</b>	\$525,386	\$1,044,036	\$2,088,073

The dilution table has been prepared on the following bases and hypothetical assumptions:

- the Company issues the maximum number of shares available under the Additional 10%;
- any increase in Variable A (being the issued share capital at the time of issue) is due to an issue of shares which is an exception in Listing Rule 7.2, for example a pro-rata rights issue. However, a 15% placement under Listing Rule 7.1 does not increase variable "A" for the purposes of calculating the placement capacity under Listing Rule 7.1A;
- the table shows only the effect of issues of shares under the Additional 10% in Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1;
- the table does not show the dilution that may be caused to any particular shareholder by reason of placements under Listing Rule 7.1A, based on that shareholder's holding at the date of the AGM. For instance, shareholders will have different outcomes depending on

- whether or not they participate in a pro-rata issue which has the effect of increasing variable "A"; and
- (e) the current share price is assumed to be \$0.155, being the closing share price on 9 October 2019 prior to finalising this Notice of Meeting.

**Purpose of the Additional 10%**

The Company may seek to issue Shares under the Additional 10% for either:

- a cash issue price. In this case, the Company may use the funds for working capital or for other corporate purposes; or
- non-cash consideration, such as for the acquisition of new assets or investments, subject to any applicable ASX requirements. In such circumstances the Company will provide a valuation of the non-cash consideration as required by Listing Rule 7.1A.3.

The Company will comply with the disclosure obligations under Listing Rules 7.1A (4) and 3.10.5A upon the issue of any Additional 10%.

**Allocation Policy**

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue under the Additional 10% placement. The identity of the allottees under the Additional 10% will be determined on a case by case basis having regard to factors including the following:

- the methods of raising funds that are available to the Company, including a rights issue or other issue in which existing shareholders can participate;
- the effect of the issue of the shares on the control of the Company;
- the financial situation and solvency of the Company; and
- advice from corporate, financial and broking advisors (if applicable).

The allottees under the Additional 10% placement have not been determined as at the date of finalisation of this Notice of Meeting and may include existing substantial shareholders and/or new shareholders. However the allottees cannot include any directors, related parties or associates of a related party of the Company without a further specific shareholder approval.

**Previous Approval**

The Company previously obtained shareholder approval under Listing Rule 7.1A at the Annual General Meeting on 22 November 2018.

**Recommendation**

The Directors believe that a majority of eligible companies would seek this form of newly available shareholder approval to enable a capital-raising to be implemented if appropriate during the following year. Accordingly, shareholder approval of this resolution is considered to be a prudent approach.

The Directors believe that this resolution will provide the Company with flexibility to raise capital quickly if advantageous terms are available, and is in the best interests of the Company. The Directors recommend that shareholders vote in favour of this resolution.

The Chairman of the meeting intends to vote undirected proxies in favour of this resolution.